This study aims to see if better skin care can help reduce skin problems like rash and paronychia (a painful finger or toe infection) in patients with a type of lung cancer called non-small cell lung cancer (NSCLC). This cancer is linked to changes in a gene called epidermal growth factor receptor (EGFR). Patients will be treated with two medicines, *amivantamab* and *lazertinib*, which are given as first-line, or initial, treatments. The study checks if enhanced skin care is better than standard care at preventing skin issues.

To join, you should have advanced or spreading NSCLC with specific gene changes. You can't have uncontrolled health issues or certain lung diseases. Also, if you have allergies to the study drugs, you can't participate. The study will last for a certain period, with regular check-ups to monitor your skin and overall health.

• Participants must have specific gene changes in their lung cancer.
• Regular check-ups required to track skin and health.
• Cannot join if you have certain lung diseases or allergies to study drugs.